Researchers at the Indian Institute of Science (IISc) in Bengaluru have identified a strategy to restore the effectiveness of isoniazid, a frontline drug used to treat tuberculosis, by combining it with another antibiotic, vancomycin.

Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, continues to remain one of the world's most persistent health challenges. What is particularly alarming, IISc said, is the bacterium's growing resistance to isoniazid.

The team tested the combination against clinical isolates of M. tuberculosis obtained from sputum samples of patients with drug-resistant TB, in collaboration with the National Tuberculosis Institute in Bengaluru. The isolates showed a broad range of isoniazid resistance, which allowed the researchers to test the combination against various resistance mechanisms.

"Isoniazid resistance poses a major challenge in the treatment of TB. To tackle this problem, we started exploring ways to rescue the drug by reversing resistance," said Nagasuma Chandra, Professor at the Department of Biochemistry and corresponding author of the study published in Microbiology Spectrum.

How the combination breaks resistance

Isoniazid is a prodrug which requires activation by a bacterial enzyme to be effective. Mutations in specific genes can create resistant bacteria that block this activation pathway.

Vancomycin, meanwhile, has difficulty penetrating the impermeable cell wall of M. tuberculosis. When the two drugs are used together, a loss of cell wall integrity allows vancomycin to enter the cell and start killing the bacteria.

"The combination substantially reduced bacterial burden compared to the individual drugs. Most of the isolates showed more than 90% reduction in bacterial growth under the combination treatment. This included isolates resistant to isoniazid as well as multidrug-resistant (MDR) isolates," IISc said.

Tenfold drop in bacterial load in mice

The researchers then tested the drug combination in a mouse model infected with an MDR strain of M. tuberculosis, in collaboration with Amit Singh, Professor at the Centre for Infectious Disease Research and the Department of Microbiology and Cell Biology at IISc.

After 10 days of treatment, neither isoniazid nor vancomycin alone produced a significant reduction in bacterial burden. The combination, however, resulted in an approximately 10-fold reduction in bacterial load in both the lungs and the spleen.

Histopathological examination also showed the combination treatment lowered the number of lung granulomas, the inflammatory structures the body forms in an unsuccessful attempt to contain the infection.

Clinical trials are the next step

The researchers stressed that the treatment is not yet ready for human use. The team is currently working to advance the combination for clinical trials, and further research is needed to establish its safety and effectiveness in people.

PhD student Sukriti Pal, the first author of the study, said several antibiotic combinations are available for TB treatment but challenges persist because of drug resistance. The new study identifies a strategy that can reverse resistance to isoniazid, an otherwise highly effective antibiotic.

If the combination clears clinical trials, it could give doctors a way to rescue one of the most effective TB drugs they already have, rather than waiting years for an entirely new medicine.